Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 7
Submit an article Journal homepage
322
Views
21
CrossRef citations to date
0
Altmetric
Special Focus: Vaccine Adjuvants - Review

Clinical vaccine development for H5N1 influenza

Christopher H Clegg TRIA Bioscience Corp., Suite 250, 1616 Eastlake Avenue East, Seattle, WA 98102, USA. [email protected]; TRIA Bioscience Corp., Suite 250, 1616 Eastlake Avenue East, Seattle, WA 98102, USA. [email protected]
,
Joseph A Rininger CaroGen Corporation, 295 Washington Ave, Suite 4N, Hamden, CT 06518, USA; CaroGen Corporation, 295 Washington Ave, Suite 4N, Hamden, CT 06518, USA
&
Susan L Baldwin Infectious Disease Research Institute, Suite 400, 1616 Eastlake Avenue East, Seattle, WA 98102, USA; Infectious Disease Research Institute, Suite 400, 1616 Eastlake Avenue East, Seattle, WA 98102, USA
Pages 767-777 | Published online: 09 Jan 2014

References

  • Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am. J. Public Health 77(6), 712–716 (1987).
  • Bosch FX, Garten W, Klenk HD, Rott R. Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of avian influenza viruses. Virology 113(2), 725–735 (1981).
  • Stephenson I. H5N1 vaccines: how prepared are we for a pandemic? Lancet 368(9540), 965–966 (2006).
  • Keitel WA, Atmar RL. Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Curr. Opin. Pharmacol. 7(5), 484–490 (2007).
  • Poland GA, Jacobson RM, Targonski PV. Avian and pandemic influenza: an overview. Vaccine 25(16), 3057–3061 (2007).
  • WHO/World Organisation for Animal Health/Food and Agriculture Organization H5N1 Evolution Working Group. Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1) [conference summary]. Emerg. Infect. Dis. [serial on the Internet] 14(7) (2008).
  • Herfst S, Schrauwen EJ, Linster M et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336(6088), 1534–1541 (2012).
  • Imai M, Watanabe T, Hatta M et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486(7403), 420–428 (2012).
  • Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J. Virol. 82(9), 4612–4619 (2008).
  • Hovden AO, Cox RJ, Haaheim LR. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand. J. Immunol. 62(1), 36–44 (2005).
  • Fritz R, Sabarth N, Kiermayr S et al. A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J. Infect. Dis. 205(1), 28–34 (2012).
  • Suguitan AL Jr, Marino MP, Desai PD et al. The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology 395(2), 280–288 (2009).
  • Steel J. New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges. BioDrugs 25(5), 285–298 (2011).
  • Keating GM, Plosker GL, Lyseng-Williamson KA. A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use. BioDrugs 26(6), 425–430 (2012).
  • Cancro MP, Hao Y, Scholz JL et al. B cells and aging: molecules and mechanisms. Trends Immunol. 30(7), 313–318 (2009).
  • Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287–293 (2009).
  • Wang Y, Rahman D, Lehner T. A comparative study of stress-mediated immunological functions with the adjuvanticity of alum. J. Biol. Chem. 287(21), 17152–17160 (2012).
  • Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229–265 (2009).
  • Flach TL, Ng G, Hari A et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17(4), 479–487 (2011).
  • McKee AS, Burchill MA, Munks MW et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc. Natl Acad. Sci. USA 110(12), E1122–E1131 (2013).
  • O’Hagan DT, Tsai T, Reed S. Emulsion-based adjuvants for improved influenza vaccine. In: Influenza Vaccines for the Future. Del Giudice G, Rappuoli R (Eds). Springer Basel AG, 327–358 (2011).
  • Klucker MF, Dalençon F, Probeck P, Haensler J. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. J. Pharm. Sci. 101(12), 4490–4500 (2012).
  • O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30(29), 4341–4348 (2012).
  • Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962–7967 (2009).
  • Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4(2), e4384 (2009).
  • Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27(45), 6284–6290 (2009).
  • Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28(3), 849–857 (2010).
  • Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198(5), 642–649 (2008).
  • Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3(2), e1665 (2008).
  • Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877–3882 (2009).
  • Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3(85), 85ra48 (2011).
  • Vesikari T, Karvonen A, Tilman S et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126(4), e762–e770 (2010).
  • Dormitzer PR, Galli G, Castellino F et al. Influenza vaccine immunology. Immunol. Rev. 239(1), 167–177 (2011).
  • Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J. Virol. 81(16), 8468–8476 (2007).
  • McKinstry KK, Strutt TM, Swain SL. Hallmarks of CD4 T cell immunity against influenza. J. Intern. Med. 269(5), 507–518 (2011).
  • Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23–32 (2009).
  • Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239(1), 178–196 (2011).
  • Shen H, Tesar BM, Walker WE, Goldstein DR. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 181(3), 1849–1858 (2008).
  • McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 71(4), 465–488 (2011).
  • Hagen SR, Thompson JD, Snyder DS, Myers KR. Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography. J. Chromatogr. A 767(1-2), 53–61 (1997).
  • Rallabhandi P, Awomoyi A, Thomas KE et al. Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J. Immunol. 180(2), 1139–1147 (2008).
  • Coler RN, Bertholet S, Moutaftsi M et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6(1), e16333 (2011).
  • Baldwin SL, Shaverdian N, Goto Y et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27(43), 5956–5963 (2009).
  • Coler RN, Baldwin SL, Shaverdian N et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5(10), e13677 (2010).
  • Behzad H, Huckriede AL, Haynes L et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205(3), 466–473 (2012).
  • Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J. Med. Microbiol. 61(Pt 7), 935–943 (2012).
  • Middleton D, Rockman S, Pearse M et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J. Virol. 83(15), 7770–7778 (2009).
  • Sambhara S, Poland GA. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic. Annu. Rev. Med. 61, 187–198 (2010).
  • Bernard A, Payton M, Radford KR. Protein expression in the baculovirus system. Curr. Protoc. Protein Sci. Chapter 5, Unit 5.5 (2001).
  • Feshchenko E, Rhodes DG, Felberbaum R et al. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol. 12, 77 (2012).
  • Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13–14), 1732–1737 (2001).
  • Kanazashi S. A Phase I/II clinical study of UMN-0501 for healthy adult males. Presented at: The 5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials (2009).
  • Clegg CH, Roque R, Van Hoeven N et al. Adjuvant solution for pandemic influenza vaccine production. Proc. Natl Acad. Sci. USA 109(43), 17585–17590 (2012).
  • D’Aoust MA, Couture MM, Charland N et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 8(5), 607–619 (2010).
  • Chichester JA, Jones RM, Green BJ et al. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses 4(11), 3227–3244 (2012).
  • Liu G, Song L, Reiserova L et al. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 30(48), 6833–6838 (2012).
  • Taylor DN, Treanor JJ, Sheldon EA et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30(39), 5761–5769 (2012).
  • Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. WHO, Geneva, Switzerland, 17–18 February 2011. Vaccine 29, 7579–7586 (2011).
  • Khurana S, Verma S, Verma N et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J. Virol. 85(3), 1246–1256 (2011).
  • Khurana S, Wu J, Verma N et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J. Virol. 85(21), 10945–10954 (2011).
  • Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42), 5393–5399 (2008).
  • Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1), e1501 (2008).
  • Landry N, Ward BJ, Trépanier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5(12), e15559 (2010).
  • Landry N. Clinical development of plant-made influenza VLP vaccines. Presented at: 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. Geneva, Switzerland 17–18 February (2011).
  • Ahmed SS, Plotkin SA, Black S, Coffman RL. Assessing the safety of adjuvanted vaccines. Sci. Transl. Med. 3(93), 93rv2 (2011).
  • Sun Y, Gruber M, Matsumoto M. Overview of global regulatory toxicology requirements for vaccines and adjuvants. J. Pharmacol. Toxicol. Methods 65(2), 49–57 (2012).
  • Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction? Eur. J. Intern. Med. 21(2), 70–73 (2010).
  • Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27(49), 6959–6965 (2009).
  • Wijnans L, Lecomte C, de Vries C et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 31(8), 1246–1254 (2013).
  • Kothare SV, Wiznitzer M. Association between H1N1 vaccination and narcolepsy-cataplexy: Flu to sleep. Neurology 80(14), 1276–1277 (2013).
  • Edwards KM, Sabow A, Pasternak A, Boslego JW. Strategies for broad global access to pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 471–493 (2009).
  • Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343–1351 (2006).
  • Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367(9523), 1657–1664 (2006).
  • Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197(5), 667–675 (2008).
  • Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin. Ther. 32(13), 2186–2197 (2010).
  • Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580–589 (2007).
  • Thongcharoen P, Auewarakul P, Hutagalung Y et al. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population. J. Med. Assoc. Thai. 94(8), 916–926 (2011).
  • Nolan TM, Richmond PC, Skeljo MV et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26(33), 4160–4167 (2008).
  • Treanor JJ, Izikson R, Dunkle L et al. Safety and immunogenicity of a recombinant hemagglutinin (rHA) pandemic H5N1 influenza vaccine. Presented at: 52nd ICAAC. San Francisco, CA, USA (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.